15:33:32 EDT Wed 22 Mar 2023
Enter Symbol
or Name

News for C:CYBN from 2022-03-23 to 2023-03-22 - 51 items News ReleasesIn The NewsOther CAUS
2023-02-28 10:09C:CYBNCybin Inc0.72News ReleaseCybin talks data from phase 1/2A CYB003 clinical trial
2023-02-22 16:46C:CYBNCybin Inc0.69News ReleaseCybin turns attention toward efficiency, trials
2023-02-14 12:31C:CYBNCybin Inc0.54News ReleaseCybin has $20-million in cash at Feb. 14
2023-02-14 07:35C:CYBNCybin Inc0.54SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-02-14 07:35C:CYBNCybin Inc0.54SEDAR MD & ASEDAR MD & A
2023-02-01 09:53C:CYBNCybin Inc0.50News ReleaseCybin receives OK for first-in-human dosing of CYB004
2023-01-26 10:59C:CYBNCybin IncNews ReleaseCybin to hold R&D day on Feb. 28
2023-01-18 13:22C:CYBNCybin Inc0.60News ReleaseCybin details partner FS on Kernel's Flow
2023-01-12 09:53C:CYBNCybin Inc0.68News ReleaseCybin selects GAD as target indication for CYB004
2023-01-09 00:55C:CYBNCybin Inc0.53News ReleaseCybin to release CYB003 interim readout by end of Feb.
2022-12-20 10:46C:CYBNCybin Inc0.38News ReleaseCybin summarizes 2022 operations
2022-12-06 16:45C:CYBNCybin Inc0.44News ReleaseCybin presents CYB003 preclincical data at ACNP
2022-11-14 22:09C:CYBNCybin Inc0.59SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2022-11-14 22:09C:CYBNCybin Inc0.59SEDAR MD & ASEDAR MD & A
2022-11-14 18:26C:CYBNCybin Inc0.59News ReleaseCybin has cash of $29.9-million on Sept. 30
2022-11-10 17:15C:CYBNCybin Inc0.57News ReleaseCybin completes dosing of four cohorts in phase 1 trial
2022-10-27 13:42C:CYBNCybin Inc0.63News ReleaseCybin facilitators graduate from Embark program
2022-10-11 00:16C:CYBNCybin Inc0.82News ReleaseCybin recognizes World Mental Health Day
2022-10-06 14:33C:CYBNCybin Inc0.85News ReleaseCybin talks patent filings
2022-09-27 11:45C:CYBNCybin Inc0.72News ReleaseMindset licenses IP for preclinical compounds to Cybin
2022-09-20 15:36C:CYBNCybin Inc0.86News ReleaseCybin achieves R&D milestones ahead of schedule
2022-08-31 09:47C:CYBNCybin Inc1.41News ReleaseCybin's Adelia achieves final milestone of 2020 deal
2022-08-30 09:44C:CYBNCybin Inc1.41News ReleaseCybin doses two patients in phase 1/2a psilocybin trial
2022-08-17 09:08C:CYBNCybin Inc1.01News ReleaseCybin receives DEA licence for phase 1/2a CYB003 trial
2022-08-15 18:16C:CYBNCybin Inc0.97News ReleaseCybin shareholders elect six directors at AGM
2022-08-09 15:16C:CYBNCybin Inc0.92Prospectus ApprovedCybin to list additional shares
2022-08-08 18:09C:CYBNCybin Inc0.92SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2022-08-08 18:09C:CYBNCybin Inc0.92SEDAR MD & ASEDAR MD & A
2022-08-08 17:49C:CYBNCybin Inc0.92News ReleaseCybin arranges $35-million (U.S.) equity program
2022-08-08 17:35C:CYBNCybin IncNews ReleaseCybin ends Q1 with cash of $42.5-million
2022-07-11 11:26C:CYBNCybin Inc0.73News ReleaseCybin completes acquisition of DMT study from Entheon
2022-06-27 19:38C:CYBNCybin Inc0.77News ReleaseCybin unit Adelia reaches Y2, Q3 (i), milestone
2022-06-27 10:15C:CYBNCybin Inc0.74News ReleaseCybin receives IND OK for phase 1/2a CYB003 trial
2022-06-22 12:52C:CYBNCybin Inc0.70News ReleaseCybin has cash position of $53.6-million at March 31
2022-06-22 07:27C:CYBNCybin Inc0.70SEDAR Annual Information FormSEDAR Annual Information Form
2022-06-22 07:27C:CYBNCybin Inc0.70SEDAR Audited Annual Financial StatementsSEDAR Audited Annual Financial Statements
2022-06-22 07:22C:CYBNCybin Inc0.70SEDAR MD & ASEDAR MD & A
2022-06-09 18:09C:CYBNCybin Inc0.78News ReleaseCybin to begin phase 1/2a clinical trial for CYB003
2022-06-07 11:17C:CYBNCybin Inc0.95News ReleaseCybin to acquire DMT study from Entheon for $1M
2022-06-03 18:27C:CYBNCybin Inc0.98News ReleaseCybin subsidiary Adelia hits $2.03M worth of milestones
2022-06-03 10:43C:CYBNCybin Inc0.95News ReleaseCybin develops Embark training program team
2022-06-02 16:16C:CYBNCybin Inc0.95News ReleaseCybin publishes peer-reviewed article about Embark
2022-05-31 10:05C:CYBNCybin Inc0.86News ReleaseCybin submits IND application to FDA for CYB003 trial
2022-04-21 10:10C:CYBNCybin Inc0.93News ReleaseCybin contracts Clinilabs for CYB003 phase 1/2a trial
2022-04-13 09:56C:CYBNCybin Inc0.93News ReleaseCybin talks up results of CYB004 inhalation study
2022-04-08 09:50C:CYBNCybin Inc0.96News ReleaseCybin applauds WIPO patent application for psychedelics
2022-04-01 10:18C:CYBNCybin Inc1.02News ReleaseCybin's Adelia meets contribution milestone
2022-03-31 14:25C:CYBNCybin Inc1.02News ReleaseCybin begins Kernel Flow feasibility study
2022-03-29 12:06C:CYBNCybin Inc0.97News ReleaseCybin's CYB003 "well tolerated" in preclinical studies
2022-03-25 11:00C:CYBNCybin Inc0.94News ReleaseCybin's Adelia meets contribution milestones
2022-03-24 13:04C:CYBNCybin Inc0.95News ReleaseCybin seeks participants for Kernel feasibility study